Review





Similar Products

90
Partek robust multi-array average (rma) algorithm with probe-level quintile normalization
Robust Multi Array Average (Rma) Algorithm With Probe Level Quintile Normalization, supplied by Partek, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/robust multi-array average (rma) algorithm with probe-level quintile normalization/product/Partek
Average 90 stars, based on 1 article reviews
robust multi-array average (rma) algorithm with probe-level quintile normalization - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
GeneCentric Diagnostics rma-normalized mrna expression data
Box plots showing the representative differential proteins in ER+PIK3CAH1047R versus ER+PIK3CAWT subgroups. a The top 5 upregulated and down-regulated proteins or phosphoproteins (y-axis by protein expression) in ER+PIK3CAH1047R patients versus ER+ PIK3CAWT subgroup, respectively. b Box plot view showing the ratio of phosphoprotein to total protein level for 2 representative proteins (AKT and YAP), phosphoprotein (STAT3) and protein (BCL-XL) differential expression, and <t>mRNA</t> differential expression for YAP1 and two YAP1 target genes (TEAD1 and CTGF) altered by PIK3CAH1047R in ER+ breast cancer. The phosphorylation sites in phosphoprotein were labeled by subscript text. The P values were calculated by Wilcoxon rank-sum test for protein differential expression analysis and by edgeR software for mRNA differential expression analysis. The detailed data are provided in Supplementary Table 3
Rma Normalized Mrna Expression Data, supplied by GeneCentric Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rma-normalized mrna expression data/product/GeneCentric Diagnostics
Average 90 stars, based on 1 article reviews
rma-normalized mrna expression data - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Partek robust multi-array average (rma) algorithm with probelevel quintile normalization
Box plots showing the representative differential proteins in ER+PIK3CAH1047R versus ER+PIK3CAWT subgroups. a The top 5 upregulated and down-regulated proteins or phosphoproteins (y-axis by protein expression) in ER+PIK3CAH1047R patients versus ER+ PIK3CAWT subgroup, respectively. b Box plot view showing the ratio of phosphoprotein to total protein level for 2 representative proteins (AKT and YAP), phosphoprotein (STAT3) and protein (BCL-XL) differential expression, and <t>mRNA</t> differential expression for YAP1 and two YAP1 target genes (TEAD1 and CTGF) altered by PIK3CAH1047R in ER+ breast cancer. The phosphorylation sites in phosphoprotein were labeled by subscript text. The P values were calculated by Wilcoxon rank-sum test for protein differential expression analysis and by edgeR software for mRNA differential expression analysis. The detailed data are provided in Supplementary Table 3
Robust Multi Array Average (Rma) Algorithm With Probelevel Quintile Normalization, supplied by Partek, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/robust multi-array average (rma) algorithm with probelevel quintile normalization/product/Partek
Average 90 stars, based on 1 article reviews
robust multi-array average (rma) algorithm with probelevel quintile normalization - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Biotechnology Information log 2 -transformed, rma (robust multichip average)-normalized, rescaling bxd hypothalamus microarray intensity data
Box plots showing the representative differential proteins in ER+PIK3CAH1047R versus ER+PIK3CAWT subgroups. a The top 5 upregulated and down-regulated proteins or phosphoproteins (y-axis by protein expression) in ER+PIK3CAH1047R patients versus ER+ PIK3CAWT subgroup, respectively. b Box plot view showing the ratio of phosphoprotein to total protein level for 2 representative proteins (AKT and YAP), phosphoprotein (STAT3) and protein (BCL-XL) differential expression, and <t>mRNA</t> differential expression for YAP1 and two YAP1 target genes (TEAD1 and CTGF) altered by PIK3CAH1047R in ER+ breast cancer. The phosphorylation sites in phosphoprotein were labeled by subscript text. The P values were calculated by Wilcoxon rank-sum test for protein differential expression analysis and by edgeR software for mRNA differential expression analysis. The detailed data are provided in Supplementary Table 3
Log 2 Transformed, Rma (Robust Multichip Average) Normalized, Rescaling Bxd Hypothalamus Microarray Intensity Data, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/log 2 -transformed, rma (robust multichip average)-normalized, rescaling bxd hypothalamus microarray intensity data/product/Biotechnology Information
Average 90 stars, based on 1 article reviews
log 2 -transformed, rma (robust multichip average)-normalized, rescaling bxd hypothalamus microarray intensity data - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Partek rma-normalized expression exported from partek genomics suite
Box plots showing the representative differential proteins in ER+PIK3CAH1047R versus ER+PIK3CAWT subgroups. a The top 5 upregulated and down-regulated proteins or phosphoproteins (y-axis by protein expression) in ER+PIK3CAH1047R patients versus ER+ PIK3CAWT subgroup, respectively. b Box plot view showing the ratio of phosphoprotein to total protein level for 2 representative proteins (AKT and YAP), phosphoprotein (STAT3) and protein (BCL-XL) differential expression, and <t>mRNA</t> differential expression for YAP1 and two YAP1 target genes (TEAD1 and CTGF) altered by PIK3CAH1047R in ER+ breast cancer. The phosphorylation sites in phosphoprotein were labeled by subscript text. The P values were calculated by Wilcoxon rank-sum test for protein differential expression analysis and by edgeR software for mRNA differential expression analysis. The detailed data are provided in Supplementary Table 3
Rma Normalized Expression Exported From Partek Genomics Suite, supplied by Partek, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rma-normalized expression exported from partek genomics suite/product/Partek
Average 90 stars, based on 1 article reviews
rma-normalized expression exported from partek genomics suite - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Partek rma normalization
Box plots showing the representative differential proteins in ER+PIK3CAH1047R versus ER+PIK3CAWT subgroups. a The top 5 upregulated and down-regulated proteins or phosphoproteins (y-axis by protein expression) in ER+PIK3CAH1047R patients versus ER+ PIK3CAWT subgroup, respectively. b Box plot view showing the ratio of phosphoprotein to total protein level for 2 representative proteins (AKT and YAP), phosphoprotein (STAT3) and protein (BCL-XL) differential expression, and <t>mRNA</t> differential expression for YAP1 and two YAP1 target genes (TEAD1 and CTGF) altered by PIK3CAH1047R in ER+ breast cancer. The phosphorylation sites in phosphoprotein were labeled by subscript text. The P values were calculated by Wilcoxon rank-sum test for protein differential expression analysis and by edgeR software for mRNA differential expression analysis. The detailed data are provided in Supplementary Table 3
Rma Normalization, supplied by Partek, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rma normalization/product/Partek
Average 90 stars, based on 1 article reviews
rma normalization - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Partek rma normalization of cel files
Box plots showing the representative differential proteins in ER+PIK3CAH1047R versus ER+PIK3CAWT subgroups. a The top 5 upregulated and down-regulated proteins or phosphoproteins (y-axis by protein expression) in ER+PIK3CAH1047R patients versus ER+ PIK3CAWT subgroup, respectively. b Box plot view showing the ratio of phosphoprotein to total protein level for 2 representative proteins (AKT and YAP), phosphoprotein (STAT3) and protein (BCL-XL) differential expression, and <t>mRNA</t> differential expression for YAP1 and two YAP1 target genes (TEAD1 and CTGF) altered by PIK3CAH1047R in ER+ breast cancer. The phosphorylation sites in phosphoprotein were labeled by subscript text. The P values were calculated by Wilcoxon rank-sum test for protein differential expression analysis and by edgeR software for mRNA differential expression analysis. The detailed data are provided in Supplementary Table 3
Rma Normalization Of Cel Files, supplied by Partek, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rma normalization of cel files/product/Partek
Average 90 stars, based on 1 article reviews
rma normalization of cel files - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
MathWorks Inc rma normalization algorithm
Box plots showing the representative differential proteins in ER+PIK3CAH1047R versus ER+PIK3CAWT subgroups. a The top 5 upregulated and down-regulated proteins or phosphoproteins (y-axis by protein expression) in ER+PIK3CAH1047R patients versus ER+ PIK3CAWT subgroup, respectively. b Box plot view showing the ratio of phosphoprotein to total protein level for 2 representative proteins (AKT and YAP), phosphoprotein (STAT3) and protein (BCL-XL) differential expression, and <t>mRNA</t> differential expression for YAP1 and two YAP1 target genes (TEAD1 and CTGF) altered by PIK3CAH1047R in ER+ breast cancer. The phosphorylation sites in phosphoprotein were labeled by subscript text. The P values were calculated by Wilcoxon rank-sum test for protein differential expression analysis and by edgeR software for mRNA differential expression analysis. The detailed data are provided in Supplementary Table 3
Rma Normalization Algorithm, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rma normalization algorithm/product/MathWorks Inc
Average 90 stars, based on 1 article reviews
rma normalization algorithm - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Thermo Fisher chp files containing signal space transformation-robust multi-array average (sst-rma) normalized data, as well as transcript annotation
Box plots showing the representative differential proteins in ER+PIK3CAH1047R versus ER+PIK3CAWT subgroups. a The top 5 upregulated and down-regulated proteins or phosphoproteins (y-axis by protein expression) in ER+PIK3CAH1047R patients versus ER+ PIK3CAWT subgroup, respectively. b Box plot view showing the ratio of phosphoprotein to total protein level for 2 representative proteins (AKT and YAP), phosphoprotein (STAT3) and protein (BCL-XL) differential expression, and <t>mRNA</t> differential expression for YAP1 and two YAP1 target genes (TEAD1 and CTGF) altered by PIK3CAH1047R in ER+ breast cancer. The phosphorylation sites in phosphoprotein were labeled by subscript text. The P values were calculated by Wilcoxon rank-sum test for protein differential expression analysis and by edgeR software for mRNA differential expression analysis. The detailed data are provided in Supplementary Table 3
Chp Files Containing Signal Space Transformation Robust Multi Array Average (Sst Rma) Normalized Data, As Well As Transcript Annotation, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chp files containing signal space transformation-robust multi-array average (sst-rma) normalized data, as well as transcript annotation/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
chp files containing signal space transformation-robust multi-array average (sst-rma) normalized data, as well as transcript annotation - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

96
Jackson Immuno rma l donkey se rum
Box plots showing the representative differential proteins in ER+PIK3CAH1047R versus ER+PIK3CAWT subgroups. a The top 5 upregulated and down-regulated proteins or phosphoproteins (y-axis by protein expression) in ER+PIK3CAH1047R patients versus ER+ PIK3CAWT subgroup, respectively. b Box plot view showing the ratio of phosphoprotein to total protein level for 2 representative proteins (AKT and YAP), phosphoprotein (STAT3) and protein (BCL-XL) differential expression, and <t>mRNA</t> differential expression for YAP1 and two YAP1 target genes (TEAD1 and CTGF) altered by PIK3CAH1047R in ER+ breast cancer. The phosphorylation sites in phosphoprotein were labeled by subscript text. The P values were calculated by Wilcoxon rank-sum test for protein differential expression analysis and by edgeR software for mRNA differential expression analysis. The detailed data are provided in Supplementary Table 3
Rma L Donkey Se Rum, supplied by Jackson Immuno, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rma l donkey se rum/product/Jackson Immuno
Average 96 stars, based on 1 article reviews
rma l donkey se rum - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

Image Search Results


Box plots showing the representative differential proteins in ER+PIK3CAH1047R versus ER+PIK3CAWT subgroups. a The top 5 upregulated and down-regulated proteins or phosphoproteins (y-axis by protein expression) in ER+PIK3CAH1047R patients versus ER+ PIK3CAWT subgroup, respectively. b Box plot view showing the ratio of phosphoprotein to total protein level for 2 representative proteins (AKT and YAP), phosphoprotein (STAT3) and protein (BCL-XL) differential expression, and mRNA differential expression for YAP1 and two YAP1 target genes (TEAD1 and CTGF) altered by PIK3CAH1047R in ER+ breast cancer. The phosphorylation sites in phosphoprotein were labeled by subscript text. The P values were calculated by Wilcoxon rank-sum test for protein differential expression analysis and by edgeR software for mRNA differential expression analysis. The detailed data are provided in Supplementary Table 3

Journal: Breast cancer research and treatment

Article Title: Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer

doi: 10.1007/s10549-016-4011-9

Figure Lengend Snippet: Box plots showing the representative differential proteins in ER+PIK3CAH1047R versus ER+PIK3CAWT subgroups. a The top 5 upregulated and down-regulated proteins or phosphoproteins (y-axis by protein expression) in ER+PIK3CAH1047R patients versus ER+ PIK3CAWT subgroup, respectively. b Box plot view showing the ratio of phosphoprotein to total protein level for 2 representative proteins (AKT and YAP), phosphoprotein (STAT3) and protein (BCL-XL) differential expression, and mRNA differential expression for YAP1 and two YAP1 target genes (TEAD1 and CTGF) altered by PIK3CAH1047R in ER+ breast cancer. The phosphorylation sites in phosphoprotein were labeled by subscript text. The P values were calculated by Wilcoxon rank-sum test for protein differential expression analysis and by edgeR software for mRNA differential expression analysis. The detailed data are provided in Supplementary Table 3

Article Snippet: We also collected microarray gene expression data for breast cancer cell lines from two sources: (i) genecentric RMA-normalized mRNA expression data across 53 breast cancer cell lines was extracted from the Genomics of Drug Sensitivity in Cancer (GDSC) database (version: updated in October, 2012) [ 24 , 25 ]; and (ii) microarray gene expression profiles across 45 breast cancer cell lines were collected from the Stand Up to Cancer (SU2C) database [ 26 ].

Techniques: Expressing, Quantitative Proteomics, Phospho-proteomics, Labeling, Software

A gene co-expression-weighted protein interaction subnetwork for YAP1 and the relationship between mRNA expression and drug responses in breast cancer cell lines based on the GDSC dataset [55]. a A gene co-expression-weighted protein interaction subnetwork connecting YAP1 and its 58 interacting proteins. The red edges denote positive co-expression and blue edges denote negative co-expression. The different color keys on nodes represent significance (P values) of gene co-expression measured by F statistics. Gene co-expression analysis was performed based on ER+PIK3CAH1047R breast invasive carcinoma dataset (RNA-seq with V2 RSEM) from TCGA. b Heat map showing the Pearson correlation coefficient (color key) between drug responses and gene mRNA expression for YAP1 and its 58 interacting genes based on the GDSC dataset [55] including 130 drugs’ response data (IC50, the natural log micromolar) and microarray expression across 53 breast cancer cell lines. The labels at the right side are genes and in the bottom are drugs. YAP1 and its two important target genes (TEAD1 and CTGF) were highlighted by red. c Four significant correlation (r: Pearson correlation coefficient) pairs between YAP1 mRNA expression and drug resistance. The P values were performed by F statistics

Journal: Breast cancer research and treatment

Article Title: Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer

doi: 10.1007/s10549-016-4011-9

Figure Lengend Snippet: A gene co-expression-weighted protein interaction subnetwork for YAP1 and the relationship between mRNA expression and drug responses in breast cancer cell lines based on the GDSC dataset [55]. a A gene co-expression-weighted protein interaction subnetwork connecting YAP1 and its 58 interacting proteins. The red edges denote positive co-expression and blue edges denote negative co-expression. The different color keys on nodes represent significance (P values) of gene co-expression measured by F statistics. Gene co-expression analysis was performed based on ER+PIK3CAH1047R breast invasive carcinoma dataset (RNA-seq with V2 RSEM) from TCGA. b Heat map showing the Pearson correlation coefficient (color key) between drug responses and gene mRNA expression for YAP1 and its 58 interacting genes based on the GDSC dataset [55] including 130 drugs’ response data (IC50, the natural log micromolar) and microarray expression across 53 breast cancer cell lines. The labels at the right side are genes and in the bottom are drugs. YAP1 and its two important target genes (TEAD1 and CTGF) were highlighted by red. c Four significant correlation (r: Pearson correlation coefficient) pairs between YAP1 mRNA expression and drug resistance. The P values were performed by F statistics

Article Snippet: We also collected microarray gene expression data for breast cancer cell lines from two sources: (i) genecentric RMA-normalized mRNA expression data across 53 breast cancer cell lines was extracted from the Genomics of Drug Sensitivity in Cancer (GDSC) database (version: updated in October, 2012) [ 24 , 25 ]; and (ii) microarray gene expression profiles across 45 breast cancer cell lines were collected from the Stand Up to Cancer (SU2C) database [ 26 ].

Techniques: Expressing, RNA Sequencing, Microarray

Relationship between YAP1 mRNA expression and drug responses in breast cancer cell lines based on the SU2C dataset [26]. a Heat map showing the Pearson correlation coefficient (color key) between drug responses and gene expression for YAP1 and its 58 interacting genes based on the SU2C dataset [26] containing 73 drugs’ response data (−log10(GI50)) and microarray expression across 45 breast cancer cell lines. The labels at the right side are genes and in the bottom are drugs. b Three significant correlation (r: Pearson correlation coefficient) pairs between YAP1 mRNA expression and drug sensitivity. The P values were performed by F statistics

Journal: Breast cancer research and treatment

Article Title: Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer

doi: 10.1007/s10549-016-4011-9

Figure Lengend Snippet: Relationship between YAP1 mRNA expression and drug responses in breast cancer cell lines based on the SU2C dataset [26]. a Heat map showing the Pearson correlation coefficient (color key) between drug responses and gene expression for YAP1 and its 58 interacting genes based on the SU2C dataset [26] containing 73 drugs’ response data (−log10(GI50)) and microarray expression across 45 breast cancer cell lines. The labels at the right side are genes and in the bottom are drugs. b Three significant correlation (r: Pearson correlation coefficient) pairs between YAP1 mRNA expression and drug sensitivity. The P values were performed by F statistics

Article Snippet: We also collected microarray gene expression data for breast cancer cell lines from two sources: (i) genecentric RMA-normalized mRNA expression data across 53 breast cancer cell lines was extracted from the Genomics of Drug Sensitivity in Cancer (GDSC) database (version: updated in October, 2012) [ 24 , 25 ]; and (ii) microarray gene expression profiles across 45 breast cancer cell lines were collected from the Stand Up to Cancer (SU2C) database [ 26 ].

Techniques: Expressing, Gene Expression, Microarray